Form 4: Enliven Therapeutics Director Richard A. Heyman Sells Shares
SEC Form 4 Filing
Richard A. Heyman, a director at Enliven Therapeutics, sold shares of the company's common stock on August 15, 2024, according to a Form 4 filing with the SEC.
Summary
- On August 15, 2024, Richard A. Heyman, a director of Enliven Therapeutics, sold 650 shares of common stock at a weighted average price of $22.8162.
- He also sold 620 shares at a weighted average price of $23.7027.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 17, 2023.
- Following these transactions, Heyman directly owns 130,373 shares of Enliven Therapeutics.
- He also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 27,918 shares through RAHD Capital LLC.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider selling. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's prospects.
Industry Context
Insider selling is a common occurrence and can be for various reasons, not necessarily indicative of the company's performance or future prospects. It's important to consider the overall context and trends in insider trading activity for Enliven Therapeutics and its peers.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the impact is likely to be minimal given the relatively small number of shares involved and the pre-planned nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| 2016-11-01 | Date of the Richard A. Heyman and Anne E. Daigle Trust |
| 2023-07-17 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 2024-08-15 | Date of the share sale transactions |
| 2024-08-19 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.